Clearmind Medicine Inc (CMND) Stock Analysis
Verdict: AVOID
Binary clinical risk combined with a $4.7M annual cash burn and $0 revenue suggests imminent dilution or insolvency despite Ph I progress.
Investment score: 12/100
Analysis as of
Is Clearmind Medicine Inc stock worth reviewing? The TradeMates thesis
The model views CMND as a distressed biotech with high insolvency risk despite recent clinical progress.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 2/100 (weight 15%)
- Earnings Quality: 10/100 (weight 15%)
- Insider Sentiment: 15/100 (weight 10%)
- Analyst Consensus: 30/100 (weight 10%)
- Risk-Adjusted Return: 5/100 (weight 15%)
Clearmind Medicine Inc opportunities and risks
What speaks for CMND
- Clinical Milestone Achievement
What speaks against CMND
- Critical Liquidity Shortfall / Dilution Risk
Peers and competitors
- BAMM.CN
- DHB.V
- ASP.TO
- MRV.TO
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CMND | n/a | 0.0x | 1.2x | 0.0% | 0.0% | -278.8% |
| BAMM.CN | n/a | 0.1x | n/a | 25.3% | -92.1% | -185.4% |
| DHB.V | n/a | 0.3x | n/a | 45.5% | -9.0% | -10.4% |
| ASP.TO | n/a | n/a | n/a | 127.1% | 857.9% | -1205.6% |
| MRV.TO | n/a | 4155.6x | 13556.2x | 64.6% | -46.7% | 0.0% |
| Peer median | n/a | 0.2x | n/a | 55.1% | -27.9% | -97.9% |
Frequently asked questions about Clearmind Medicine Inc (CMND)
Is CMND stock a good investment?
The TradeMates model rates Clearmind Medicine Inc as AVOID with an investment score of 12/100. The model views CMND as a distressed biotech with high insolvency risk despite recent clinical progress. This is algorithmic model output, not personal investment advice.
Is CMND stock a buy?
The TradeMates model verdict for CMND is AVOID with an investment score of 12/100. Treat this as a model signal to review, not a personal buy recommendation.